Financial
Oct. 4, 2018 Bioasis Announces Investor Relations Service Agreement with Stern IR
GUILFORD, Conn.–(Business Wire)–Bioasis Technologies, Inc. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has engaged Stern Investor Relations, Inc. (“Stern… Read more »
Aug. 31, 2018 Bioasis Announces Stock Option Grants
GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options… Read more »
Aug. 13, 2018 Bioasis Announces Closing of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Jul. 30, 2018 Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
RICHMOND, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
Jul. 16, 2018 Bioasis Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Jun. 26, 2018 Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
RICHMOND, British Columbia & GUILFORD, Conn–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it… Read more »
May. 24, 2018 Bioasis Announces Closing of Second Tranche of Previously Disclosed Private Placement
This News Release is Not for Distribution to U.S. Newswire Services or Dissemination in the United States
May. 14, 2018 Bioasis Announces Private Placement and Intention to Pursue NASDAQ Listing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Jan. 30, 2018 Bioasis Announces Filing of Quarterly Financial Statements and MD&A
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the central nervous system for the treatment of neurological diseases and disorders, today announced that it has filed its unaudited quarterly financial statements and management’s discussion and… Read more »
Aug. 28, 2017 biOasis Announces Nominees to the Board of Directors, Chairman Transition and Details of its Annual General Meeting of Shareholders
New Board nominees include accomplished biopharmaceutical executives Nancy Stagliano, Ph.D., CEO at True North Therapeutics; Deborah Rathjen, Ph.D., CEO & Managing Director of Bionomics; and Maha Radhakrishnan, M.D., SVP & Head of World Wide Medical at Bioverativ Therapeutics Inc. biOasis Founder Mr. Rob Hutchison will step down as Chairman of the Board on Dec. 31, 2017